keyword
MENU ▼
Read by QxMD icon Read
search

lung non small cell cancer

keyword
https://www.readbyqxmd.com/read/29161765/mir-335-inhibited-cell-proliferation-of-lung-cancer-cells-by-target-tra2%C3%AE
#1
Jian Liu, Tingting Bian, Jia Feng, Li Qian, Jianguo Zhang, Daishan Jiang, Qing Zhang, Xiaoli Li, Yifei Liu, Jiahai Shi
Accumulating evidence has suggested that the dysregulation of miRNAs is an important factor in the pathogenesis of lung cancer. Here, we demonstrate that miR-335 expression is reduced in non-small cell lung cancer (NSCLC) tumors relative to non-cancerous adjacent tissues, whilst the expression of Tra2β is increased. In addition, clinical data revealed that the increased Tra2β and decreased miR-335 expression observed in NSCLC cells was associated with poor patient survival rates. In-vitro experimentation showed that the overexpression of miR-335 inhibited the growth, invasion and migration capabilities of A459 lung cancer cells, by targeting Tra2β...
November 21, 2017: Cancer Science
https://www.readbyqxmd.com/read/29161357/nivolumab-in-non-small-cell-lung-cancer-with-egfr-mutation
#2
H Yoshida, Y H Kim, H Ozasa, H Nagai, Y Sakamori, T Tsuji, T Nomizo, Y Yasuda, T Funazo, T Hirai
No abstract text is available yet for this article.
November 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29160382/lung-cancer-changes-in-histology-gender-and-age-over-the-last-30-years-in-brazil
#3
Maria Teresa Ruiz Tsukazan, Álvaro Vigo, Vinícius Duval da Silva, Carlos Henrique Barrios, Jayme de Oliveira Rios, José Antônio de Figueiredo Pinto
OBJECTIVE: To describe the trends in tumor histology, gender and age among patients with non-small cell lung cancer (NSCLC) treated with lung resection. The histology of lung cancer has changed in developed countries, and there is still little information available on the topic for developing countries. METHODS: This was a retrospective study of 1,030 patients with NSCLC treated with lung resection between 1986 and 2015 at a university hospital in southern Brazil...
September 2017: Jornal Brasileiro de Pneumologia: Publicaça̋o Oficial da Sociedade Brasileira de Pneumologia e Tisilogia
https://www.readbyqxmd.com/read/29159957/evaluating-performance-of-a-user-trained-mr-lung-tumor-autocontouring-algorithm-in-the-context-of-intra-and-inter-observer-variations
#4
Eugene Yip, Jihyun Yun, Zsolt Gabos, Sarah Baker, Don Yee, Keith Wachowicz, Satyapal Rathee, B Gino Fallone
PURPOSE: Real-time tracking of lung tumors using magnetic resonance imaging (MRI) has been proposed as a potential strategy to mitigate the ill-effects of breathing motion in radiation therapy. Several autocontouring methods have been evaluated against a "gold standard" of a single human expert user. However, contours drawn by experts have inherent intra- and inter-observer variations. In this study, we aim to evaluate our user-trained autocontouring algorithm with manually drawn contours from multiple expert users, and to contextualize the accuracy of these autocontours within intra- and inter- observer variations...
November 21, 2017: Medical Physics
https://www.readbyqxmd.com/read/29159913/a-small-organic-molecule-blocks-egfr-transport-into-the-nucleus-by-the-non-classical-pathway-resulting-in-repression-of-cancer-invasion
#5
Siyoung Ha, Jangho Jeong, Jiwon Oh, Sangmyung Rhee, Seung Wook Ham
In addition to the traditional epidermal growth factor receptor (EGFR) signaling pathways, nuclear EGFR has been shown to control multiple cellular functions, including cell proliferation and invasion. It has been reported that EGFR is transported into the nucleus after forming a complex with KPNA/KPNB1 or KPNB1. In this study, we have shown that EGFR can interact with both KP and KPNA, but EGF-activated EGFR mostly binds with KPNB1 through the pull-down assay. We also found that a small organic molecule (compound 1), an effective binder of KPNB1, inhibited the interaction between EGFR and KPNB1 in the non-classical transport pathway, but not KPNA...
November 20, 2017: Chembiochem: a European Journal of Chemical Biology
https://www.readbyqxmd.com/read/29159778/risk-of-leptomeningeal-carcinomatosis-in-patients-with-brain-metastases-treated-with-stereotactic-radiosurgery
#6
Rosaline Ma, Morgan Levy, Bin Gui, Shou-En Lu, Venkat Narra, Sharad Goyal, Shabbar Danish, Simon Hanft, Atif J Khan, Jyoti Malhotra, Sabin Motwani, Salma K Jabbour
There is limited available literature examining factors that predispose patients to the development of LMC after stereotactic radiosurgery (SRS) for brain metastases. We sought to evaluate risk factors that may predispose patients to LMC after SRS treatment in this case-control study of patients with brain metastases who underwent single-fraction SRS between 2011 and 2016. Demographic and clinical information were collected retrospectively for 19 LMC cases and 30 controls out of 413 screened patients with brain metastases...
November 20, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29158850/mmpp-attenuates-non-small-cell-lung-cancer-growth-by-inhibiting-the-stat3-dna-binding-activity-via-direct-binding-to-the-stat3-dna-binding-domain
#7
Dong Ju Son, Jie Zheng, Yu Yeon Jung, Chul Ju Hwang, Hee Pom Lee, Ju Rang Woo, Song Yi Baek, Young Wan Ham, Min Woong Kang, Minho Shong, Gi Ryang Kweon, Min Jong Song, Jae Kyung Jung, Sang-Bae Han, Bo Yeon Kim, Do Young Yoon, Bu Young Choi, Jin Tae Hong
Rationale: Signal transducer and activator of transcription-3 (STAT3) plays a pivotal role in cancer biology. Many small-molecule inhibitors that target STAT3 have been developed as potential anticancer drugs. While designing small-molecule inhibitors that target the SH2 domain of STAT3 remains the leading focus for drug discovery, there has been a growing interest in targeting the DNA-binding domain (DBD) of the protein. Methods: We demonstrated the potential antitumor activity of a novel, small-molecule (E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol (MMPP) that directly binds to the DBD of STAT3, in patient-derived non-small cell lung cancer (NSCLC) xenograft model as well as in NCI-H460 cell xenograft model in nude mice...
2017: Theranostics
https://www.readbyqxmd.com/read/29158808/distant-metastasis-and-survival-outcomes-after-computed-tomography-guided-needle-biopsy-in-resected-stage-i-iii-non-small-cell-lung-cancer
#8
Yuhui Xi, Jingli Fan, Dehai Che, Keke Zhai, Tingting Ren, Xiao Feng, Lihua Shang, Jing Hu, Yan Yu, Qingwei Meng
Background and objective Several reports describe the needle-tract implantation after percutaneous needle lung biopsy. The present study evaluated whether preoperative computed tomography-guided needle biopsy (CTNB) affected the distant metastasis and overall survival in patients with early non-small cell lung cancer (NSCLC). Methods A total of 1667 patients with pathological stage I-III NSCLC were assimilated. Of these, 168 patients received preoperative CTNB, whereas 1499 patients were not subjected to any biopsy before surgical resection...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158797/pd-l1-is-a-prognostic-biomarker-in-resected-nsclc-patients-with-moderate-high-smoking-history-and-elevated-serum-scca-level
#9
Lianjing Cao, Xinyue Wang, Shouying Li, Qiongjie Zhi, Yuqian Wang, Liuchun Wang, Kai Li, Richeng Jiang
Programmed cell death-1 (PD-1) -targeted immunotherapy has become a promising treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC). Clinical responses to checkpoint inhibition therapy in NSCLC have been associated with programmed death-1 ligand 1 (PD-L1) expression. However, the association between the expression of PD-L1 and PD-L2 and the clinicopathological features and patient outcomes in NSCLC remain unclear. We retrospectively analyzed 364 patients (158 squamous cell carcinoma and 206 adenocarcinoma) who underwent complete resection between 2009 and 2012...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158791/correlation-of-cancer-stem-cell-markers-and-immune-cell-markers-in-resected-non-small-cell-lung-cancer
#10
Zhaoqin Huang, Haining Yu, Jianbo Zhang, Haiyan Jing, Wanqi Zhu, Xiaolin Li, Lingling Kong, Ligang Xing, Jinming Yu, Xiangjiao Meng
Background: Recent studies confirmed that immunotherapy showed prominent efficacy in non-small cell lung cancer (NSCLC). Cancer stem cells/cancer initiating cells are resistant to anticancer treatment. The purpose of the study was to analyze the correlation of cancer stem cells/cancer initiating cells and tumor-infiltrating immune cells in NSCLC. Methods: CD133, octamer 4 (OCT-4), CD8, CD56, human leukocyte antigen (HLA) class I and programmed death ligand-1 (PD-L1) were assessed in 172 resected NSCLC samples...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158696/65plus-open-label-study-of-bevacizumab-in-combination-with-pemetrexed-or-pemetrexed-carboplatin-as-first-line-treatment-of-patients-with-advanced-or-recurrent-nonsquamous-non-small-cell-lung-cancer
#11
Wolfgang Schuette, Claus-Peter Schneider, Walburga Engel-Riedel, Christian Schumann, Martin Kohlhaeufl, Monika Heidi Ursel Serke, Gert Hoeffken, Cornelius Kortsik, Martin Reck
Background: The aim of the study was to investigate in terms of noninferiority the efficacy and safety of a monochemotherapy regimen of pemetrexed plus bevacizumab (BevPem) versus carboplatin/pemetrexed plus bevacizumab (BevCPem) in elderly patients as first-line treatment for advanced metastatic or recurrent nonsquamous non-small-cell lung cancer (NSCLC). Materials and methods: 65Plus was a Phase III, randomized, open-label study. In total, 253 patients received BevPem (n=119) or BevCPem (n=134)...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/29158124/improved-survival-with-increased-time-to-radiation-and-sequential-chemotherapy-after-surgery-for-pn2-non-small-cell-lung-cancer
#12
Karna Sura, Inga S Grills, Charles C Vu, Craig W Stevens, Hong Ye, Thomas M Guerrero
BACKGROUND: Currently, the ideal timing for postoperative radiotherapy (PORT) and chemotherapy is unknown. The present study evaluated their relative timing on overall survival (OS) using the National Cancer Database (NCDB). MATERIALS AND METHODS: The NCDB was queried for patients from 2004 to 2012 with resected non-small-cell lung cancer (NSCLC), pathologically involved N2 (pN2) nodes, and negative margins. All patients underwent adjuvant chemotherapy and external beam radiotherapy...
November 17, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29158123/efficacy-and-safety-of-necitumumab-continuation-therapy-in-the-phase-iii-squire-study-of-patients-with-stage-iv-squamous-non-small-cell-lung-cancer
#13
Tudor Ciuleanu, Mark A Socinski, Coleman Obasaju, Alexander V Luft, Aleksandra Szczesna, Wojciech Szafrański, Rodryg Ramlau, Beatrix Bálint, Olivier Molinier, Henrik Depenbrock, Shivani Nanda, Luis Paz-Ares, Nick Thatcher
INTRODUCTION: In a retrospective analysis of the SQUamous NSCLC treatment with the Inhibitor of EGF REceptor (SQUIRE) study, we investigated the efficacy and safety of single-agent necitumumab continuation therapy in patients with stage IV squamous non-small-cell lung cancer and in a subpopulation of patients with epidermal growth factor receptor (EGFR)-expressing tumors. PATIENTS AND METHODS: Patients were randomized 1:1 for ≤ 6 cycles of gemcitabine and cisplatin either with or without necitumumab...
October 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29157814/mistletoe-viscum-album-extract-targets-axl-to-suppress-cell-proliferation-and-overcome-cisplatin-and-erlotinib-resistance-in-non-small-cell-lung-cancer-cells
#14
Soyoung Kim, Kyung-Chan Kim, ChuHee Lee
BACKGROUND: Mistletoe extract of Visucm album extract (VAE) contains many biologically active components and has been reported to be not only a complementary and alternative medicine, but also a potent therapeutic agent for many types of cancer. PURPOSE: In this study, we examined the effect of VAE on expression and activation of Axl and scrutinized the involvement of Axl in the anti-cancer activity of VAE in parental and chemo-resistant non-small cell lung cancer (NSCLC) cells...
December 1, 2017: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/29157387/non-small-cell-lung-cancer-pet-imaging-beyond-f18-fluorodeoxyglucose
#15
REVIEW
Gang Cheng
F18 Flurodeoxyglucose (FDG) is a nonspecific PET tracer representing tumor energy metabolism, with common false-positive and false-negative findings in clinical practice. Non-small cell lung cancer is highly heterogeneous histologically, biologically, and molecularly. Novel PET tracers designed to characterize a specific aspect of tumor biology or a pathway-specific molecular target have the potential to provide noninvasive key information in tumor heterogeneity for patient stratification and in the assessment of treatment response...
January 2018: PET Clinics
https://www.readbyqxmd.com/read/29157386/prognostic-value-of-18-f-fluorodeoxyglucose-pet-computed-tomography-in-non-small-cell-lung-cancer
#16
REVIEW
Gang Cheng, He Huang
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death with a poor prognosis. Numerous factors contribute to treatment outcome. 18F-fluorodeoxyglucose (FDG) uptake reflects tumor metabolic activity and is an important prognosticator in patients with NSCLC. Volume-based FDG-PET parameters reflect the metabolic status of a malignancy more accurately than maximum standardized uptake value and thus are better prognostic markers in lung cancer. FDG-avid tumor burden parameters may help clinicians to predict treatment outcomes before and during therapy so that treatment can be adjusted to achieve the best possible outcomes while avoiding side effects...
January 2018: PET Clinics
https://www.readbyqxmd.com/read/29157385/treatment-planning-for-radiation-therapy
#17
REVIEW
Michael MacManus, Sarah Everitt
PET scanning plays key roles in planning the management of patients with lung cancer who are candidates for curative-intent treatment with radiotherapy and has contributed to improvements in survival. (18)F-fluorodeoxyglucose-PET is the most important modality for staging, patient selection, and radiotherapy target volume definition in patients with unresectable non-small cell lung cancer. Developments include the availability of alternative tracers, such as (18)F-fluorothymidine, for imaging proliferation and a range of hypoxia imaging agents...
January 2018: PET Clinics
https://www.readbyqxmd.com/read/29157384/genomic-characterization-of-lung-cancer-and-its-impact-on-the-use-and-timing-of-pet-in-therapeutic-response-assessment
#18
REVIEW
Lavinia Tan, Benjamin Solomon
Significant advances in understanding the genomic landscape of non-small cell lung cancer (NSCLC) together with the coupling discovery of key oncogenic drivers and the development of effective targeted and immunotherapeutic agents have revolutionized the management of this malignancy. Although these therapies have resulted in improved outcomes for a subgroup of patients, their benefit may not necessarily be reflected by conventional response assessment criteria, because these therapeutic agents differ in their mechanism of action and response time compared with cytotoxic chemotherapy...
January 2018: PET Clinics
https://www.readbyqxmd.com/read/29157380/staging-of-non-small-cell-lung-cancer
#19
REVIEW
Tim Akhurst
Staging of lung cancer serves 2 purposes; it attempts to classify patients into groups where particular treatments are appropriate and defines those groups based on expected prognosis. The eighth edition of the International Association for the Study of Lung Cancer staging system deals with the issues raised by screening with fine cut computed tomography. Each phase of staging is a legitimate dataset on its own. Molecular profiling of lung cancer has led to the development of an increasing number of novel agents to treat systemic disease...
January 2018: PET Clinics
https://www.readbyqxmd.com/read/29157298/impressive-response-to-immunotherapy-in-a-metastatic-gastric-cancer-patient-could-somatic-copy-number-alterations-help-patient-selection
#20
Gustavo Dos Santos Fernandes, Daniel da Motta Girardi, Luiza Dib Batista Bugiato Faria, João Paulo Giacomini Bernardes, Renata de Almeida Coudry
BACKGROUND: Metastatic gastric cancer (GC) is an incurable and aggressive disease with a poor prognosis. Immunotherapy is an attractive approach for treating patients with cancer, and studies using immunotherapy have shown promising results in melanoma, kidney and non-small cell lung cancers, among others. CASE PRESENTATION: We present a case of a 50-year-old woman with metastatic GC whose cancer had progressed after first-line chemotherapy and who received pembrolizumab as an experimental treatment...
November 21, 2017: Journal for Immunotherapy of Cancer
keyword
keyword
97811
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"